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Abstract
Background: Leprosy is a disease of skin and peripheral nerves. The process of nerve injury occurs gradually through the
course of the disease as well as acutely in association with reactions. The INFIR (ILEP Nerve Function Impairment and
Reactions) Cohort was established to identify clinically relevant neurological and immunological predictors for nerve injury
and reactions.
Methodology/Principal Findings: The study, in two centres in India, recruited 188 new, previously untreated patients with
multi-bacillary leprosy who had no recent nerve damage. These patients underwent a series of novel blood tests and nerve
function testing including motor and sensory nerve conduction, warm and cold detection thresholds, vibrometry,
dynamometry, monofilament sensory testing and voluntary muscle testing at diagnosis and at monthly follow up for the
first year and every second month for the second year. During the 2 year follow up a total of 74 incident events were
detected. Sub-clinical changes to nerve function at diagnosis and during follow-up predicted these new nerve events.
Serological assays at baseline and immediately before an event were not predictive; however, change in TNF alpha before
an event was a statistically significant predictor of that event.
Conclusions/Significance: These findings increase our understanding of the processes of nerve damage in leprosy showing
that nerve function impairment is more widespread than previously appreciated. Any nerve involvement, including sub-
clinical changes, is predictive of further nerve function impairment. These new factors could be used to identify patients at
high risk of developing impairment and disability.
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Introduction
Leprosy is a disease of skin and peripheral nerves, as well as other
organs, resulting from the interaction between Mycobacterium leprae
and the host response. The involvement of the skin aids early
detection and diagnosis while the injury to the motor, sensory and
autonomic function of peripheral nerves leads to progressive
impairment of both structure and function. Nerve injury occurs
gradually through the course of the disease as well as acutely in
association with rapid changes in immune responses commonly
known as reactions. Over the past decade a number of important
cohort studies in Ethiopia [1] , Thailand [2] and Bangladesh [3]
have advanced our knowledge of the epidemiology of and clinical
risk factors for neuropathy and reactions in leprosy. Multibacillary
forms of leprosy, increasing age, and evidence of existing nerve
impairment are strongly predictive of new nerve function
impairment and reactions which have a peak in occurrence 3–4
monthsafterstarting chemotherapy.A clinical predictionrulebased
on typeof leprosy and presenceof nerve function impairment neatly
summarised the key risk factors [4].
Similarly understanding of the mechanisms of nerve injury and
reactions in leprosy has increased over the past decade starting with
the potential processes by which M.leprae binds to laminin in the
basement lamina of the Schwann cell [5,6]. The uptake of M.leprae by
Schwann cells is associated with an inflammatory response and local
oedema leading to demyelination [7]. Further work is needed to
elaborate the mechanisms of nerve injury and reactions in leprosy.
Recent trials in Nepal and Bangladesh [8] have investigated
prevention of nerve damage and reactions using low dose steroids.
This research demonstrated a reduction in the incidence of new
www.plosntds.org 1 August 2009 | Volume 3 | Issue 8 | e500reactions and nerve function impairment in the short term but this
effect was not sustained at one year. The reduction was greater in
those with no nerve function impairment at diagnosis. Treatment
trials of reactions using steroids have shown that long courses are
better than shorter courses but their effectiveness is limited [9]
while other studies have demonstrated that recovery can occur
spontaneously without treatment [10].
Further studies combining both basic research and epidemiol-
ogy are needed to elucidate the mechanisms of nerve damage and
reactions. The INFIR (ILEP Nerve Function Impairment and
Reactions) Cohort Study [11] was established to identify clinically
relevant neurological and immunological predictors for nerve
injury and reactions both at diagnosis and immediately preceding
events. New evidence on the risk factors that predict future
neuropathy and reactions will contribute to understanding
mechanisms as well as being clinically important in targeting
follow-up of high risk individuals and in the development of
strategies for early detection and prevention. The aim of this study
is to assess whether novel haematological, immunological, and
neurological parameters measured at diagnosis and prior to events
can predict neuropathy and reaction events in patients with newly
diagnosed untreated multibacillary leprosy independently of
established clinical risk factors.
Methods
Newly diagnosed, previously untreated, multibacillary leprosy
patients were recruited at one of two specialist leprosy referral centres
(The Leprosy Mission Hospitals at Naini and Faizabad) in Uttar
Pradesh, North India. Patients who were slit skin smear positive and/
or had six or more skin lesions and/or had involvement of two or
more nerve trunks were eligible for inclusion. Eligible patients were
invited to participate through a process of informed consent and
commencedonafullcourseofmultibacillary(MB)multidrugtherapy
(MDT). A standardised history using a checklist was taken from all
patients recruited to the study and a clinical and neurological
examination conducted which included nerve function assessment
with motor and sensory nerve conduction testing, warm and cold
detection thresholds, vibrometry, dynamometery, monofilament and
voluntary muscle testing [11]. Blood sampling and a skin biopsy was
performed at recruitment and the specimens were analysed at the
Stanley Browne Laboratories in Miraj, Maharashtra and LEPRA
Blue Peter Research Centre in Hyderabad. The blood samples were
assayed by ELISA for anticeramide and S100 antibodies (Sigma
Chemicals, USA), and for antibodies against LAM (lipoarabinoman-
nan) and PGL-1 (phenolic glycolipid 1) provided by Professor
Brennan, USA. Serum TNF-alpha was also estimated by ELISA.
Thepatientswerefollowedupmonthlyforoneyearandeverysecond
month during the second year when repeat nerve function assessment
and blood samples were collected.
The outcome events for the analysis presented here included a
first occurrence of neuritis, type 1 or reversal reaction, type 2 or
erythema nodosum leprosum, new sensory impairment or new
motor impairment based on clinical assessments [11]. Excluded
were patients exhibiting signs of reaction at diagnosis or reporting
recent onset changes in sensory or moter nerve function, recent
being defined as duration of 6 months or less. The analysis of risk
factors was based on two categories of outcomes – all first incident
events (ALL) and first incident events which included new nerve
function impairment (NFI). These categories were selected based
on expected numbers of events sufficient to conduct analyses and
providing categories that represented sufficiently distinct groups.
Some patients experienced multiple recurrent or chronic events
during follow-up. Identification of risk factors for these outcomes is
beyond the scope of the present paper.
The factors included in the analysis were grouped into two types,
established factors and novel factors which had not been formally
tested in a large enough cohort study. The established risk factors
were based on the findings of previous cohort studies [1–3] and
which areclinically and routinely measured. In an initial analysis we
assessed the predictive value of these variables for the Cohort data
and identified a subset with optimal predictive value.
Novel factors are those included in this study that have not been
previously assessed in terms of their ability to predict events
independent of the established clinical factors. For novel neurological
factors, impaired status was defined by applying reference values
computed from studies of normal subjects resident in the study area
but having no known neurological condition (Papers submitted).
Using Cox Proportional Hazard Regression analysis, univariate
hazard ratios were calculated for all novel factors at diagnosis and at
the assessment immediately prior to the incident event. Hazard ratios
for factors measured at two assessments before an event and the
change between one and two assessments prior to an event were also
calculated, though inevitably this data was unavailable for the 15
patients who had an incident event diagnosed at the first follow-up
after diagnosis. Risk factors which showed a hazard ratio that was
significantly different from 1 were re-analysed, adjusting for the
optimal subset of established risk factors described above.
The overall sample size calculation for the Cohort Study was
based on a risk factor present in 20% of the study population and
an outcome frequency in the unexposed of 5%. A sample size of
240 was needed to detect a relative risk of 4 and 200 to detect a
20% difference between predictive values. A sample size of 300
was planned based on an estimated loss to follow-up of 10–20%.
The exclusions from the analysis presented here caused a
reduction in sample size and inevitable reduction in statistical
power. Our presentation of results therefore focuses on findings
that were replicated across nerves and across nerve functions.
Ethical Considerations
Ethical approval for the study was given by the Research Ethics
Committee of the Central JALMA Institute for Leprosy in Agra.
Informed, written consent was obtained from the study partici-
Author Summary
Leprosy is a disease of skin and peripheral nerves. The skin
changes aid early detection and diagnosis, while the nerve
damage leads to progressive impairment and disability.
The aim of this study was to identify new risk factors at
diagnosis and during follow-up that would predict which
patients would develop nerve damage. The study, in two
centres in India, recruited 188 new previously untreated
patients with multi-bacillary leprosy who had no recent
nerve damage. These patients underwent a series of novel
blood tests and nerve function testing as diagnosis and at
monthly follow up. Evidence of sub-clinical changes to
nerve function at diagnosis and during follow-up predict-
ed new nerve damage. None of the blood tests at
diagnosis predicted further nerve damage while changes
to one serological marker, TNF alpha, before an event were
predictive. These findings increase our understanding of
the processes of nerve damage in leprosy showing that
nerve function impairment is more widespread than
previously appreciated and that any nerve involvement is
predictive of further nerve function impairment. These
new factors could be used to identify patients at high risk
of developing impairment and disability.
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form. No financial incentives were given to participants however
travel expenses were refunded and where relevant compensation
for lost earnings for daily workers.
Results
The Cohort
The INFIR study cohort recruited 303 new MB leprosy patients,
including 115 who had reactions or new neuropathy at the time of
diagnosis.Theanalysisidentifyingriskfactorsforafirstincidentevent
is therefore based on the 188 patients with no baseline reactions or
new neuropathy within the 6 months prior to diagnosis. 78.6%
completed MDT and 12 months follow-up. Most were male (71.8%).
143 (76%) had self-reported signs and symptoms of leprosy of more
than 6 months duration including 79 (42%) for more than one year.
Mostwere classifiedas BorderlineTuberculoid BT (66.0%) byRidley
Jopling classification, the remainder were Borderline Lepromatous
BL (23.4%) and Lepromatous Lepromatous LL (10.6%). 28% had
positive slit skin smear tests and 72% negative. Most had evidence of
at least one enlarged nerve (81.4%) and 28% had more than 4
enlarged nerves.
Incident Events
74 first incident events were detected through routine assessment
and self reporting based on clinical examination including clinical
nerve function assessment by sensory and voluntary muscle testing.
The survival curve is shown in Figure 1 where 62.2% of first events
occurred in the first 4 months and only 7 first events occurred in the
second year of follow-up. Of the 74 events, 69 were classed as type 1
(reversal reactions) and 5 as type 2 (ENL reactions), and in 54 the
event included a change in nerve function.
Clinical and Demographic Factors and the Risk of New
Events
Seventy four (39.4%) patients (ALL) out of the cohort of 188
had a reaction or nerve function impairment event, in 54 patients
this included new nerve function impairment (NFI) . The hazards
ratios for the first event (ALL and NFI) for the clinically assessed
factors from the history and routine examination are presented in
Table 1. The risk of an event increased significantly with
increasing age and those having an event were on average 6.5
years older than those who remained event free but there was no
difference in risk between men and women. There was little
difference in the event rate by clinical classification being 39.5% in
BT, 40.9% in BL, and 35.0% in LL patients, and no relationship
with being skin smear positive or delay in diagnosis was observed.
Nerve enlargement was significantly associated with increased risk
of events, both ALL events and NFI events. Having a higher
number of skin lesions was associated with increased risk of an
event but this was not statistically significant. On the basis of these
observations age, sex, nerve enlargement and number of skin
Figure 1. Kaplan-Meier survival to first incident event and to first event with new NFI.
doi:10.1371/journal.pntd.0000500.g001
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the analyses assessing the predictive value of novel factors.
Clinically measured nerve function impairment was not used as
a covariate as this was the method used to diagnose new events.
Haemoglobin levels and a white cell count at diagnosis were not
predictive of events.
Novel Risk Factors Assessed at Diagnosis
Neurological factors. Cox proportional hazard ratios for
any new event for abnormalities in motor or sensory nerve
conduction velocity, latency or amplitude, for loss warm or cold
thermal sensation or reduced vibration perception for each nerve
trunk tests were calculated, including adjustments for age, sex,
nerve enlargement and number of skin lesions. All those reaching
statistical significance are reported here.
Abnormalities in motor nerve conduction in the ulnar nerve
(above the elbow and at the wrist), the median nerve (at the elbow
and at the wrist) and the peroneal nerve (at the fibular head and at
the ankle) were associated with an increased risk but none were
statistically significantly predictive of any new event. Abnormalities
in sensory nerve conduction in the ulnar, median and radial
cutaneous nerves but not the sural nerve were significantly
associated with new events (Figure 2). Only ulnar sensory nerve
conduction and radial cutaneous sensory nerve conduction were
statistically significant after adjustment. Abnormality in warm
sensation in the skin areas supplied by the ulnar nerve and the
posterior tibial nerve were significant predictors of new events but
were not significant after adjustment. Abnormality in vibration
sensation in the ulnar, median, radial cutaneous, posterior tibial
and sural nerves were not predictive of future events.
The same Cox proportional hazard analyses were conducted for
the same neurological variables this time predicting nerve function
impairment events (Figure 2). Abnormalities in motor nerve
conduction tended to be associated with an increased risk of an
NFI event but this was only significant for the peroneal nerve at
the ankle and this was not significant after adjustment.
Abnormalities in sensory nerve conduction in all nerves tested
were significantly associated with an increased risk of a new nerve
function impairment with hazard ratios of around 2, and all
remained significant after adjustment except median nerve
conduction amplitude and latency in the sural nerve. Abnormal-
ities of warm sensation in the ulnar, radial cutaneous, posterior
tibial and sural nerves were predictive for new NFI events, but
only in the posterior tibial nerve was this significant after
adjustment. Abnormalities in cold sensory function in the radial
cutaneous, posterior tibial and sural nerves were predictive for new
NFI events but only in the sural nerve did this remain significant
after adjustment. Only abnormality in vibration sensation in the
ulnar nerve was predictive of new NFI events but this was not
significant after adjustment.
Immunological and serological. The hazards ratios for
both ALL new events and for nerve function impairment (NFI)
events for serum anticeramide, serum TNF alpha, PGL 1 IgG and
IgM, serum S100, and serum LAM IgG are presented in Table 2.
None are significantly different from 1.
Novel Risk Factors Assessed Immediately before a New
Event
Neurological. Abnormalities in motor nerve conduction in
the assessment prior to a new NFI event showed a trend across the
nerves tested to predict the event and the effect of abnormalities in
sensory nerve conduction was similar but stronger than that for
motor nerve conduction. In sensory nerve conduction the hazard
ratios for an NFI event were higher in the assessment immediate
preceding the event compared to the one before as seen in Figure 3
for the median, ulnar, and radial cutaneous nerves.. Hazard ratios
for abnormalities in motor and sensory nerve conduction in the
assessment before an event were greater for NFI events than for
ALL events.
Immunological and serological. The serological assays
prior to an event were not predictive of the event however
change in TNF alpha between the assays one and two assessments
before an event was statistically significantly (p=0.009) different
from one (Figure 3).
Discussion
This is an important study which comprehensively assesses
novel risk factors for nerve function impairment and reactions in
leprosy using rigorous methods and extensive and careful follow-
up over 24 months. The study builds on existing knowledge of
clinical and demographic risk factors for reactions and for new
nerve function impairment occurring during and after MDT.
Using data from the INFIR Cohort Study, the analysis focuses on
the 188 patients with newly diagnosed multibacillary leprosy who
had no recent nerve function impairment or reactions at the time
of diagnosis. The clinical and demographic risk factors demon-
strated a level of risk similar to other cohort studies [1–3]
recognising that this cohort was restricted to multibacillary
patients so that bacteriological index, Ridley-Jopling classification
and number of lesions were less predictive in this more
homogenous cohort. None of the haematological factors measured
were predictive of events.
Predictive value of neurological status at diagnosis
Abnormalities in motor nerve conduction at diagnosis showed a
tendency towards increased risk for ALL events. While individ-
ually these failed to reach statistical significance, a similar pattern
was found for both latency and amplitude in all nerves tested.
Table 1. Clinical risk factors, numbers at risk and univariate
hazard ratios and 95% confidence intervals for ALL new events
and for new nerve function impairment events (NFI).
Numbers at risk, hazard ratios and confidence intervals
N All Events NFI Events
Age
Up to 25 69 1 1
26–40 73 1.29 (0.72–2.34) 1.51 (0.69–3.33)
41+ 46 2.29 (1.28–4.08) 3.90 (1.88–8.09)
Sex
Male 135 1 1
Female 53 0.93 (0.56–1.53) 0.97 (0.53–1.76)
Nerve Enlargement
More than 4 21 1.15 (1.01–1.31) 1.23 (1.06–1.44)
Lesions
0–5 34 1 1
6–10 39 1.74 (0.78–3.88) 1.42 (0.59–3.42)
More than 10 115 1.54 (0.76–3.15) 1.15 (0.53–2.49)
ALL includes all new skin and nerve function impairment events of both
reversal and type 2 reactions in the 188 patients with no recent events at
diagnosis. NFI includes only events which had new nerve function impairment.
doi:10.1371/journal.pntd.0000500.t001
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conduction abnormalities at diagnosis compared to motor nerve
conduction with ulnar and radial cutaneous nerve conduction
remaining statistically significant after adjustment, the pattern for
amplitude and latency was similar. Abnormalities in warm and
cold thresholds at diagnosis were predictive of ALL events but the
effect disappeared after adjustment, any effect of vibration
sensation also disappeared on adjustment.
When the analysis was restricted to the 54 patients whose new
event included nerve function impairment both motor and sensory
nerve conduction were more strongly predictive, particularly
sensory nerve conduction where hazard ratios were around 2 and
Figure 2. Adjusted hazard ratios attached to assessments of baseline motor and sensory nerve conduction for ALL and NFI
outcome events.
doi:10.1371/journal.pntd.0000500.g002
Table 2. Hazard ratios for abnormalities in serology and immunology for ALL events and for NFI events.
Hazard Ratios and 95% confidence intervals for ALL and NFI outcomes attached to impaired values for serological
markers at baseline.
N, median, IQR ALL events NFI Events
Anticeramide 186, 0.62, 0.36–0.99 1.17 (0.67–2.04) 1.02 (0.51–2.03)
S100 188, 53.0, 34.5–85.0 0.80 (0.49–1.30) 0.65 (0.35–1.20)
TNF Alpha 188, 2.14, 0.71–17.19 0.73 (0.36–1.46) 0.69 (0.29–1.61)
PGL1_IgG 188, 63.5, 29.50–106.95 1.34 (0.81–2.20) 1.07 (0.60–1.90)
PGL1_IgM 188, 66.5, 38–120 1.29 (0.79–2.10) 1.01 (0.57–1.77)
LAM_IgG1 188, 1.0, 0–15 0.90 (0.56–1.46) 1.02 (0.58–1.79)
LAM_IgG3 188, 4.0, 3–10 0.96 (0.60–1.54) 0.99 (0.57–1.74)
doi:10.1371/journal.pntd.0000500.t002
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doi:10.1371/journal.pntd.0000500.g003
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thermal and vibration sensation disappeared after adjustment.
These motor and sensory nerve conduction findings confirm that
any nerve function impairment at diagnosis is predictive of events,
particularly events which include new nerve function impairment.
This confirms the clinico-pathological observation that inflamma-
tion in leprosy once established is very difficult to switch off [12].
However the widespread nature of the effect is important as the
effect is seen across all peripheral nerve tested. The apparent
predictive effect of vibration and thermal sensation disappears on
adjustment largely due to age as a confounding factor as has been
observed elsewhere [13].
Predictive value of serological status at diagnosis
The serological measures selected for this study were those that
had been associated with bacterial load [14], nerve damage [15]
and reactions [16] in leprosy in previous studies. Measures of LAM
antibody and anti PGL1 at diagnosis were inter-correlated and
related to bacteriological index but they did not predict events when
measured at diagnosis in this multibacillary cohort. Measures of S
100 and anticeramide were also inter-correlated (r=0.40) but they
were not related to the extent of nerve damage or to reactions at
diagnosis and did not predict future events.
Predictive value of neurological status prior to an
incident event
The pattern of effect of abnormalities in motor and sensory
nerve conduction immediately prior to an event was similar to that
at diagnosis where sensory nerve conduction had a stronger and
more consistent effect than motor nerve conduction, and the effect
was stronger for NFI events than for ALL events. Abnormalities in
sensory nerve conduction one month prior to an event have a
stronger effect than two months prior to the event. An analysis of
early diagnosis of neuropathy in leprosy in this study cohort
reported that sensory nerve conduction was the most frequent and
earliest affected test [17]. These findings may be influenced by the
staging of symptoms that varies between individual nerves and the
variation in reported duration of symptoms prior to diagnosis.
Predictive value of serological status prior to an incident
event
A change in TNF alpha levels rather than the absolute level
prior to an event was predictive, consistent with the findings in
previous smaller studies [18,19]. The levels of expression of TNF
alpha showed considerable individual variation and the rate of
change appeared to be the important predictive factor rather than
the absolute level.
This carefully conducted cohort study has confirmed the
importance of the clinical risk factors of age, classification, and
pre-existing nerve damage as predictors of new nerve function
impairment and reactions. Abnormalities in motor and sensory
nerve conduction at diagnosis and before events have been
demonstrated to be predictive of future events. Sensory nerve
conduction is a stronger predictor than motor nerve conduction
and is independent of the established clinical risk factors,
particularly events that include nerve function impairment.
Thermal and vibration sensation shows some evidence of being
predictive but this appears to be confounded by age. Serological
measures of antibodies to nerve components and to M.leprae cell
wall antigens are not predictive of new events but changes in TNF
alpha levels occur prior to new events. These findings expand our
understanding of the process of nerve function impairment in
leprosy showing that nerve involvement is much more widespread
and occur earlier than previously understood, and that any nerve
involvement is predictive of further impairment. These parameters
can be used to identify individual patients at high risk of
developing further nerve damage.
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